Olmesartan Medoxomil/Amlodipin Ascend (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartan Medoxomil/Amlodipin Ascend, is an angiotensin II receptor blocker (ARB) presented as a oral tablet for hypertension management in adult patients. It helps lower blood pressure and reduce cardiovascular risk.

GNH USA supplies Olmesartan Medoxomil/Amlodipin Ascend as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olmesartan Medoxil/Amlodipine is used in cardiovascular therapy targeting the renin‑angiotensin system and calcium‑channel pathways. - Hypertension: Provides effective blood pressure reduction when monotherapy is insufficient. - Chronic heart failure: Improves symptoms and may reduce hospitalisation risk in patients with reduced ejection fraction. - Diabetic nephropathy: Slows progression of kidney damage associated with type 2 diabetes.

Adverse reactions may occur with any antihypertensive regimen and should be monitored.

Common Side Effects: - Dizziness or light‑headedness - Peripheral edema - Headache - Flushing - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Angio‑edema - Severe hypotension - Hepatic enzyme elevation - Jaundice - Acute kidney injury - Myocardial infarction in susceptible patients

When prescribing Olmesartan Medoxil/Amlodipine, clinicians should consider several safety aspects. - Monitor blood pressure: Adjust dose if target is not reached. - Assess renal function: Use caution in patients with impaired kidneys. - Check electrolytes: Watch for potassium abnormalities. - Evaluate hepatic status: Use with care in liver disease. - Review concomitant medications: Avoid drugs that may cause additive hypotension. - Store at ambient temperature: Keep below 25°C in the original packaging, protected from moisture.

Olmesartan Medoxil/Amlodipine may interact with several drug classes, requiring clinical awareness.

Major Interactions (Avoid): - Potassium‑rich supplements or salts: Increases risk of hyper‑kalemia. - Aliskiren combined with ACE‑inhibitors or ARBs in diabetic patients: Heightened risk of renal impairment. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): May raise amlodipine levels.

Moderate Interaction : - Non‑steroidal anti‑inflamatory  g     \  ");